A Review of Hepatitis C Virus (HCV) and the Current Management of Genotype 1 Chronic HCV Infection
Background: Chronic Hepatitis C virus (HCV) is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end- stage liver disease. The addition of protease inhibitor with peginterferon alfa and ribavirin (triple therapy) for genotype 1 infected patients, are the current standard of care.
Method: Data was sourced from available journals and internet based search using pubmed, medline and google search.
Results: successful Treatment of Genotype 1 HCV infected patients with protease inhibitor based triple therapy has improved sustained virologic response (SVR) rates and treatment induced clearance of HCV infection.
Conclusion: significant progress in the management of chronic hepatitis C genotype 1 with the introduction of protease inhibitor (PI) in 2011 with peginterferon and ribavirin has optimized sustained virologic response (SVR).
Keywords: Hepatitis C genotype 1; Pegylated Interferon (Peg IFN); Protease inhibitors (PI), Telaprevir (TVR), Boceprevir (BOC), Ribavirin(RBV).
Copyright belongs to the Nigerian Medical Association (Rivers State Branch).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. It is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.